Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma
|
Duke University Medical Center / Gerard Blobe, MD, PhD |
Reach Grants |
2013 |
North Carolina |
Adoptive Immunotherapy of Tr1 Cells to Improve Outcome of Allo-HSCT Treatment for Pediatric AML |
Stanford University / Maria-Grazia Roncarolo, MD & Rosa Bachetta, MD |
Reach Grants |
2015 |
California |
Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma
|
Beckman Research Institute of City of Hope / Margarita Gutova, MD |
Reach Grants |
2013 |
California |
Targeting PI3Kdelta in Childhood Acute Lymphoblastic Leukemia |
Children’s Hospital Los Angeles / Yong-mi Kim, MD & Nora Heisterkamp, PhD |
Reach Grants |
2015 |
California |
Moving EphB4 Therapeutics to Pediatric Phase I/II Trials |
Oregon Health & Science University / Charles Keller, MD |
Reach Grants |
2013 |
Oregon |
Combining Oncolytic Vaccinia Virus with GD2.CAR-modified Vaccinia Virus-specific T-cells for the Treatment of Relapsed Neuroblastoma and Sarcoma |
Baylor College of Medicine / Cliona Rooney, PhD |
Reach Grants |
2013 |
Texas |
Phase I Study of Lentivirus Engineered Autologous AML Cells Expressing IL-12 in Children and Young Adults with Relapsed AML |
Children’s Hospital of Wisconsin - Milwaukee / Michael Burke, MD & Jeffrey Medin, MD/PhD |
Reach Grants |
2017 |
Wisconsin |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Epigenetic Targeted Therapy and Resistance in Pediatric Rhabdoid Tumor |
Ann & Robert H. Lurie Children’s Hospital of Chicago / Rintaro Hashizume, MD/PhD |
Reach Grants |
2018 |
Illinois |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |